Janssen Biotech, Inc.

Janssen Pharmaceutica Nv

Mark Tornetta

John Wheeler

Jinquan Luo

Sheng-Jiun Wu

Michael Naso

Natalie Fursov

Karen Duffy

Roberta Lamb

Ravi Malaviya

LeRoy Hall

Catherine Healy

Michael Pratta

Alexey Teplyakov

Ricardo Attar

Francois Gaudet

Yingzhe Li

Suzanne Edavettal

Kodandaram Pillarisetti

Nathan Majewski

Mark Mendonca

Leopoldo L Luistro, Iii

Diana Chin

Juan C Almagro

David M Knight

Raymond W Sweet

William Strohl

Ping Tsui

Brian Whitaker

Jin Lu

Colleen Kane

Qiang Chen

Patrick Branigan

Susann Taudte

Bernard Amegadzie

Ramachandra Reddy

Leopoldo Luistro

Lei Shi

Lionella Borozdina-Birch

Leroy Hall

Juan Carlos Almagro

Kondandaram Pillarisetti

Provided herein are antibodies that specifically bind to GPRC5D. Also described are related polynucleotides capable of encoding the provided GPRC5D-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor GPRC5D-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with GPRC5D-expressing cancer and thus may be amenable to treatment with a GPRC5D-specific anti-cancer therapeutic, such as the multispecific antibodies against GPRC5D and CD3 described herein.

Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereof

The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.

ST2L antagonists and methods of use

ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions

ST2L antibody antagonists

Described and claimed herein are combinatorial synthetic Fab libraries displayed on a phage pIX protein. The libraries were built on scaffolds representing the most frequently used genes in human antibodies, which were diversified to mirror the variability of natural antibodies. After selection using a diverse panel of proteins, numerous specific and high-affinity Fabs were isolated. By a process called in-line maturation the affinity of some antibodies was improved up to one hundred-fold yielding low pM binders suitable for in vivo use. This work thus demonstrates the feasibility of displaying complex Fab libraries as pIX-fusion proteins for antibody discovery and lays the foundations for studies on the structure-function relationship of antibodies.

[object Object]

The present invention relates to target binding members (e.g., antibodies) that bind a specified epitope of human IL-25. The invention also relates to target binding members (e.g., antibodies) that comprise one or more humanized antibody VL domain sequences and bind IL-25. The invention further relates to compositions comprising target binding members (e.g., antibodies) that bind IL-25, methods of producing such target binding members, and uses of such target binding members for the treatment or prevention of diseases and conditions (e.g., asthma, inflammatory bowel disease).

Humanized IL-25 antibodies

Growing community of inventors

Collegeville, PA, United States of America

Mark Tornetta